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NDUFB10The tyrosine kinase Src is upregulated in several cancer cells. In such cells, there is a metabolic reprogram-
ming elevating aerobic glycolysis that seems partly dependent on Src activation. Src kinase was recently
shown to be targeted to mitochondria where it modulates mitochondrial bioenergetics in non-proliferative
tissues and cells. The main goal of our study was to determine if increased Src kinase activity could also in-
ﬂuence mitochondrial metabolism in cancer cells (143B and DU145 cells). We have shown that 143B and
DU145 cells produce most of the ATP through glycolysis but also that the inhibition of OXPHOS led to a sig-
niﬁcant decrease in proliferation which was not due to a decrease in the total ATP levels. These results indi-
cate that a more important role for mitochondria in cancer cells could be ensuring mitochondrial functions
other than ATP production. This study is the ﬁrst to show a putative inﬂuence of intramitochondrial Src ki-
nase on oxidative phosphorylation in cancer cells. Indeed, we have shown that Src kinase inhibition led to
a decrease in mitochondrial respiration via a speciﬁc decrease in complex I activities (NADH–ubiquinone ox-
idoreductase). This decrease is associated with a lower phosphorylation of the complex I subunit NDUFB10.
These results suggest that the preservation of complex I function by mitochondrial Src kinase could be impor-
tant in the development of the overall phenotype of cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
While differentiated cells rely mainly on oxidative phosphoryla-
tion (OXPHOS) to produce ATP, cancer cells are generally seen as
highly glycolytic cells because they produce a large amount of lactate
regardless of oxygen availability [1,2]. Otto Warburg initially
explained this high aerobic glycolysis by an OXPHOS defect [2,3]. It
is now accepted that cancer cells may reprogram their metabolism
in this way to sustain a high proliferative phenotype. For example,
the stabilization of hypoxia-inducible factor 1-α (HIF1-α) induces a
switch of energy metabolism from mitochondrial to glycolytic,
including the up-regulation of glucose transporters and glycolytic
enzymes as well as the inhibition of pyruvate dehydrogenase [4,5].
However, even if the mitochondria produce less ATP [6], they are
still essential since most lipid, protein and nucleic acid biosynthetic
machineries use precursors derived from the TCA cycle in prolifera-
tive cells [7]. Therefore, mitochondrial regulation pathways could be
devoted to preserving mitochondrial function without relying too
much on OXPHOS.x: +33 05 57 57 16 12.
(E. Hebert-Chatelain).
l rights reserved.The tyrosine kinase Src, which is overexpressed or up-regulated in
several cancer cells, is involved in several physiological processes
such as increased cell survival, proliferation and metastatic properties
[8–10]. Src activation can also induce the remodeling of energetic me-
tabolism via the stabilization of HIF1-α and increased activities of
several glycolytic enzymes [11,12]. On the other hand, recent papers
have shown that Src kinase could be targeted to mitochondria
where it modulates OXPHOS. Indeed, Src kinase phosphorylates cyto-
chrome c oxidase (complex IV) subunit II in osteoclasts, resulting in
the activation of the enzyme [13,14]. The Src and Lck-mediated phos-
phorylation of Y190 and Y194 in adenine nucleotide translocase was
shown to be involved in its carrier function and in the respiration of
yeast [10]. The enzymatic activity of ATP synthase (complex V) is de-
creased by Src-dependent phosphorylation, while the activity of com-
plex IV is increased with Src activation in rat brain mitochondria
[15,16]. However, the possible involvement of Src kinase in the regu-
lation of mitochondrial metabolism in cancer cells still needs to be
established.
Since Src kinase is highly activated in several cancer cells, the main
goal of our study was to determine if Src kinase activity could inﬂu-
ence mitochondrial metabolism in such cells. First, we showed that
143B and DU145 cells produce most of the ATP through glycolysis
but also that the inhibition of OXPHOS led to a signiﬁcant decrease
in proliferation that was not due to a decrease in the total ATP level.
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nase in the 143B and DU145 cell lines. By using two different speciﬁc
Src inhibitors, PP2 and SU6656, we showed that the inhibition of Src
kinase leads to a speciﬁc decrease in mitochondrial respiration and
complex I enzymatic activities, probably via the reduced phosphory-
lation of the complex I subunit NDUFB10. Our results suggest that
Src kinase may be involved in the maintenance of mitochondrial func-
tions that are important for the proliferative properties of cancer cells
other than energy production.
2. Materials and methods
2.1. Chemicals
The mouse monoclonal antibody to phosphotyrosine (PY20), the
mousemonoclonal antibody to c-Src, the mousemonoclonal antibody
to LAMP-2, the rabbit polyclonal antibody to calregulin and the
mouse monoclonal antibody to Bcl-2 were bought from Santa Cruz
Biotechnology. Antibodies to phosphorylated Src species (PY419-
Src) were bought from Cell Signaling.
The Src kinase inhibitors PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine) and SU6656 were from Calbio-
chem. All antibodies against OXPHOS complexes (except NDUFB10
bought from Abcam) were bought from Mitosciences. Protease and
phosphatase cocktail inhibitors were bought from Roche. All other
chemicals were from Sigma.
2.2. Cell culture
The human osteosarcoma cell line 143B TK- and the human pros-
tate cancer cell line DU145 were maintained in culture with high glu-
cose (4.5 g l−1) DMEM (Dulbecco's modiﬁed Eagle's medium)
supplemented with 2 mM glutamine, 1 mM pyruvate and 10% (v/v)
fetal bovine serum. The 143B and DU145 cells were also grown in ga-
lactose medium, which consisted of DMEM without glucose, supple-
mented with 10 mM galactose, 2 mM glutamine, 1 mM sodium
pyruvate and 10% fetal bovine serum. The cells grown in glucose
DMEM will be referred to as 143B glu and DU145 glu whereas the
cells grown in galactose will be referred to as 143B gal and DU145
gal. All of the cells were maintained in their respective medium for
at least 5 passages before analysis. All of the cells were kept in a 5%
CO2 atmosphere at 37 °C and the medium was renewed every 2 to
3 days. Analysis and cell harvesting were always performed when
conﬂuency was about 80–90%.
2.3. Isolation of mitochondria
The cells were harvested, resuspended in isolation buffer (250 mM
sucrose, 1 mM EDTA, 5 mM HEPES, pH 7.4) containing protease and
phosphatase inhibitor cocktails and disrupted with 25 strokes using a
25-gage syringe. The cell debris and nuclei were removed by
centrifugation at 400 g for 5 min (4 °C). The supernatant was kept and
then centrifuged at 10,000 g for 10 min (4 °C). The pellet was then
resuspended and the centrifugation cycle was repeated. Mitochondria
were obtained from the last pellet. Cytosolic contamination was
evaluated by measuring the lactate dehydrogenase (LDH) activity in
the total cell lysate (TCL) and mitochondrial fractions. The LDH
activity measurements revealed poor cytosolic contamination as the
LDH activity in the mitochondrial fractions represented only
1.42±0.55% of the TCL LDH activity (n=8). Moreover, the
immunodetection of α-tubulin among the total cell lysate and mito-
chondrial fractions showed no signal for the cytosolic protein in themi-
tochondrial fractions (data not shown). These preliminary experiments
clearly minimized the possibility of cytosolic Src contamination in the
mitochondrial fractions.2.4. Oxygraphic measurements
Mitochondrial oxygen consumption assayswere performedusing the
high-resolution respirometry systemOxygraph-2k (OROBOROS INSTRU-
MENTS, Austria). Cell respiration was measured at 5∗105 cells ml−1
according to volume-speciﬁc ﬂux at 37 °C in 2 ml chambers at a stirring
rate of 750 rpm. Firstly, three different states of endogenous respiration
with intact cells were measured: (i) basal respiration representing the
endogenous physiological coupled state, (ii) respirationwith oligomycin
(2 μg ml−1) representing the non-coupled resting respiration, and (iii)
maximal uncoupled respiration induced by CCCP (0.5 μM steps with
2 μM ﬁnal concentration) providing a measure of the maximal capacity
of ETS under conditions of physiological substrate supply in the intact
cell.
Respirationwas alsomeasured in cells permeabilized with digitonin
(0.3 μg/106 cells) in respiration buffer (75 mM mannitol, 25 mM su-
crose, 100 mM KCl, 10 mM Tris–phosphate, 10 mM Tris/HCl, 50 mM
EDTA, pH 7.4). The use of this respiration buffer lowered the digitonin
concentrations in order to ensure sufﬁcient permeabilization and de-
creased the possibility of a loss in the integrity of the mitochondrial
membrane. The digitonin amount was selected in order to obtain a
maximal increase in respirationwith the rotenone–succinate–ADP sub-
strates without further stimulation by the addition of cytochrome c
(data not shown). Notably, the basal O2 consumption measured in
the respiration buffer (143B glu: 34.56±15.06 pmol O2 s−1 10−6
cells; DU145 glu: 57.22±30.96 pmol O2 s−1 10−6 cells; 143B gal:
25.53±9.37 pmol O2 s−1 10−6 cells; DU145 gal: 65.89±
11.62 pmol O2 s−1 10−6 cells) was not different from the respiration
rate measured in DMEM (p>0.05). Complex I-driven state III respira-
tion (St3 PMD) was measured with pyruvate (5 mM), malate (2 mM)
and ADP (5 mM). Complex II-driven state III respiration (St3 SD) was
measured with rotenone (0.5 μM), succinate (10 mM) and ADP
(5 mM).
2.5. Identiﬁcation of the Src target proteins in complex I
Mitochondria were incubated with ATP without or with PP2
(20 μM), as in [15–17]. The treated samples were incubated overnight
with complex I-agarose beads conjugated (Mitosciences, OR) then
eluted with glycine buffer and the samples were ﬁnally processed
for western blotting, as in [18]. Phosphotyrosines were then immuno-
detected using the PY20 antibody. The tyrosine-phosphorylated com-
plex I subunit was identiﬁed by determining the peptides present in
the phosphotyrosine signal. The spot of interest was digested by tryp-
sin as indicated in [18]. The peptides were further analyzed by nano-
liquid chromatography coupled to a MS/MS LTQ-Orbitrap XL mass
spectrometer, as detailed in [16].
2.6. Measurements of mitochondrial membrane potential and ROS levels
After treatment, the cells were harvested. Then 5∗105 cells were
incubated for 10 min at 37 °C with 50 nM tetramethylrhodamine
methyl ester perchlorate (TMRM), 50 nM CM-H2DCFDA or 50 nM
MitoSox (Invitrogen, USA). The ﬂuorescence of each probe was read
as per the manufacturer's recommendation on a spectroﬂuorometer
(SAFAS).
2.7. Gel electrophoresis and western blotting
The samples were subjected to SDS-PAGE (10 or 12.5%) and the
separated proteins were transferred onto a nitrocellulose or PVDF
membranes as already described in [17]. Primary antibodies were
revealed with a horseradish peroxidase-conjugated F(ab′)2 fragment
of anti-mouse, anti-rabbit or anti-goat IgG, F(ab′)2 fragment-speciﬁc
(Jackson ImmunoResearch Laboratories, West Grove, PA). The blots
were visualized using enhanced chemiluminescence (ECL) Plus from
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the Image J (NIH) software.
2.8. Statistical analysis
A Student's t-test was used to compare the means with the control
values using the Excel software (12.2.8). Signiﬁcance was assessed at
the 0.05 (or lower) level for all tests.
3. Results
3.1. Mitochondria seem to play an important role in cancer cells in
function(s) other than energy production
The glycolytic- and mitochondrial-dependent steady-state ATP
levels were measured in the 143B and DU145 cells grown in glucose
or galactose DMEM, as in [19]. When the 143B and DU145 cells
were maintained in glucose DMEM, mitochondrial ATP production
represented about 10% of the total ATP levels, while this mitochondri-
al ATP production was increased to approximately 50% for the 143B
cells and 75% for the DU145 cells maintained in galactose medium
(Fig. 1A).
The proliferation capacities of the 143B and DU145 cells grown in
glucose DMEM supplemented with increasing doses of OXPHOS in-
hibitors during a 5 day period were then evaluated by trypan blue
staining. As mitochondria produce as little as 10% of the total ATP in
143B and DU145 cells (Fig. 1A), we expected that the inhibition of mi-
tochondrial ATP production would have little or no impact on prolif-
eration. Interestingly, cells treated with rotenone or oligomycin for
5 days decreased proliferative capacity by more than 50% (Fig. 1BFig. 1. Steady-state ATP level in the 143B and DU145 cells. (A) ATP steady-state levels (pm
(indicative of glycolytic ATP production) or 500 μM iodoacetate (indicative of mitochond
shown as means (S.D.). (B) Proliferation of 2000 cells grown in high glucose DMEM supple
gomycin (2, 10, 20, 40, 60 nM). Cells were counted by trypan blue staining after 5 days of tre
cells treated with high glucose DMEM supplemented with rotenone (40 ng/ml) for 5 days. N
are shown as means (S.D.).and C). As seen in Fig. 1C, the total ATP levels were not changed
when OXPHOS was inhibited by rotenone for 5 days, showing that
the reduction in proliferation was not due to a decline in ATP produc-
tion. These ﬁrst results suggest that a more important role for cancer-
cell mitochondria could be to ensure other mitochondrial function(s)
than preserving ATP production.
We then examined if Src kinase could help maintain such mito-
chondrial function(s) in cancer cells such as 143B and DU145.
3.2. A fraction of Src kinase locates to the mitochondria of 143B and
DU145 cells
The fractionation of the DU145 cells on a sucrose gradient
revealed that only Src kinase and mitochondria, as shown by the la-
beling of the 70 kDa subunit of succinate-coenzyme Q reductase
(complex II), were present in fractions 6 and 7 (Fig. 2A), suggesting
that this kinase could be located to the mitochondria. Src kinase
was also present in fractions containing lysosome and endoplasmic
reticulum. A similar Src kinase localization after a sucrose gradient
was observed in the 143B cells (data not shown).
To examine the topological features of Src in mitochondria, we
performed trypsin protection assays in the presence or absence of
the detergent Triton X-100 using fractions 6 and 7 of both cell
types. Indeed, any protein not imbedded within the organelle is avail-
able to trypsin cleavage while mitochondrial membranes protect
intramitochondrial proteins from protease activity. As shown in
Fig. 2B, the subunit I of Complex IV, which is located at the level of
the mitochondrial inner membrane, is protected from trypsin diges-
tion in the absence of detergent whereas Bcl 2, an antiapoptotic pro-
tein associated with the outer membrane, is completely degraded byole) were measured with 100000 cells incubated with vehicle, 2 μg ml−1 oligomycin
rial ATP production) for both cell lines in both culture conditions. Data (n=5) are
mented with different concentrations of rotenone (1, 2, 4, 10 and 40 ng ml−1) and oli-
atment (n=5). (C) Mitochondrial and glycolytic ATP levels were measured in 100000
o statistical difference was noted, according to a Student's t-test (p>0.05). Data (n=5)
Fig. 2. Src kinase is located within the mitochondria of the 143B and DU145 cells.
(A) Organelles were separated by ultracentrifugation (100000∗g for 4 h) on a discon-
tinuous sucrose gradient (30–60%). Each fraction was then western blotted: lysosomes
were immunodetected using the LAMP2 antibody, endoplasmic reticulum with the cal-
regulin antibody, mitochondria with the succinate dehydrogenase A (SDHA) subunit
antibody and Src kinase with the Src B12 antibody. (B) Fractions 6 and 7 (from panel
A) were untreated or incubated with trypsin in the presence or absence of Triton
X-100 and then western blotted for localization of Src kinase: COX I was used as marker
of the intramitochondrial proteins while Bcl 2 was used as marker of the extramito-
chondrial proteins. (C) Isolated mitochondria were untreated or incubated with ATP,
with DMSO (as a control) or with increasing concentrations of Src inhibitor PP2 and
then western blotted. Phosphotyrosine was detected using the PY20 antibody while
the SDHA antibody was used as a loading control.
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Src to trypsin proteolysis in the absence of detergent suggests that
Src kinase is located within the mitochondria of 143B and DU145
cells (Fig. 2B).
3.3. Impact of Src kinase activity on the mitochondrial bioenergetics of
143B and DU145 cells
The activity of Src kinase in the mitochondria was then studied by
analyzing the tyrosine phosphorylation status of mitochondrial
proteins in the presence of PP2, a speciﬁc Src inhibitor [16,17]. The
incubation of mitochondria with ATP increased the level of tyrosine-
phosphorylated proteins as compared to the non-treated mitochon-
dria (Fig. 2C, lane 2). The intensity of the phosphotyrosine signal
diminished with the increased inhibition of Src activity by PP2
(Fig. 2C, lanes 3–5), showing that Src kinase is an important player
in the total mitochondrial tyrosine phosphorylation activity in 143B
and DU145 cells.
To determine if the inhibition of Src kinase could inﬂuence mito-
chondrial metabolism, we incubated the 143B and DU145 cells with
two speciﬁc and structurally non-related Src kinase inhibitors, PP2
[20] and SU6656 [21], for 4 h. The treatment of both cell lines with
5 μM PP2 or 10 μM SU6656 did not affect cell viability (143B control
cells: 100.0±11.0%; 143B PP2-treated cells: 98.5±14.4%, p>0.05;
143B SU6656-treated cells: 108.8±6.2%, p>0.05; DU145 controlcells: 100.0±9.5%; DU145 PP2-treated cells: 96.0±28.8%, p>0.05;
DU145 SU6656-treated cells: 121.2±18.9%, p>0.05; n=5) accord-
ing to the neutral red assay [22].
After treatment with Src inhibitors, Src activation was evaluated
by the immunodetection of phosphorylated Y419 residue of Src
(PY419-Src). As shown in Fig. 3A, Src activation in mitochondria iso-
lated from the 143B and DU145 cells was signiﬁcantly reduced as
compared to the untreated cells, without inﬂuencing the amount of
total Src kinase.
Different steps of mitochondrial respiration (basal respiration, oli-
gomycin respiration and uncoupled respiration) were measured in
the intact cells. The basal and uncoupled respirations were signiﬁ-
cantly higher (pb0.05) for the cells maintained in galactose DMEM
as compared to the cells maintained in glucose medium (Table 1). Oli-
gomycin respiration was similar (p>0.05) between both culture con-
ditions (Table 1). These results are consistent with the Crabtree effect
observed in cancer cells: in high-glucose medium, a minimum
amount of OXPHOS substrates enters into the mitochondria, explain-
ing whymitochondrial ATP production and respiration are lower than
in galactose medium. The Crabtree effect can be circumvented by
using galactose DMEM. Galactose is not oxidized via glycolysis, there-
by forcing cells to use glutamine and subsequent mitochondrial-
dependent ATP production [22–24]. These results also demonstrate
that mitochondria are not impaired per se in 143B and DU145 cells.
After the PP2 and SU6656 treatments, the basal and uncoupled
respiration signiﬁcantly decreased (pb0.05) in each cell line (Fig. 3B
and C). The same decrease in respiration was observed in both the
glucose and galactose DMEM for the 143B and DU145 cells, indicating
that Src inﬂuence on respiration does not depend on the bioenergetic
phenotype. The reduction of O2 consumption during uncoupled respi-
ration suggests that Src kinase may modulate OXPHOS via one com-
ponent of the ETS. To determine which ETS complexes were
targeted by Src kinase, ADP-stimulated respiration was measured by
using different respiratory substrates (pyruvate–malate or succinate)
in permeabilized cells. Src inhibition induced a clear decrease in mito-
chondrial respiration when ETS was energized with complex I sub-
strates but no effect was noted with the substrate of complex II
(Fig. 4A and B). These results suggest that Src kinase mainly inﬂu-
ences OXPHOS via complex I.
Complex I enzymatic activity was also strongly decreased in cells
treated with the inhibitors (Fig. 4B). In contrast, no signiﬁcant effect
was observed for complex II, III and IV activities in the treated cells
(Fig. 4B). Overall, these results show that Src kinase mainly regulates
the bioenergetics of 143B and DU145 cells via complex I activity.
Citrate synthase activity, which is a reliable marker of mitochon-
drial content [25], was not changed in the treated cells (Fig. 4C),
showing no change in mitochondrial content. The western blotting
analysis of NDUFS2 and COXII as markers of complex I and complex
IV, respectively, showed that the level of both complexes was not af-
fected by the treatments (Fig. 4D). Moreover, the BN-PAGE analyses
showed that the native complex I amount did not change after Src in-
hibition in both cell lines (data not shown), suggesting that the com-
plex I assembly process was not impaired.
3.4. Identiﬁcation of the Src-mediated phosphorylation site in complex I
The reduction in complex I activities could not be explained by the
lower protein content, suggesting that its enzymatic activities were
affected through post-translational modiﬁcations. In order to identify
which subunit of complex I was differentially targeted by Src kinase
among the treatments, complex I was immunoprecipitated from mi-
tochondria of 143B and DU145 cells that were preincubated with
ATP in the presence or absence of PP2, and analyzed by western blot-
ting. As shown in Fig. 5, a tyrosine-phosphorylated band of about
20 kDa was observed after incubation with ATP and not (or to a
lower intensity) when Src kinase was inhibited by PP2. Mass
Fig. 3. Effect of Src inhibition on the bioenergetics of the 143B and DU145 cells. Cells were incubated for 4 h with DMEM supplemented with DMSO or Src inhibitors PP2 (5 μM) and
SU6656 (10 μM). (A) After treatment, the mitochondria were isolated and immunoblotted with the PY419-Src and porin antibodies, stripped and reprobed with the Src B12 anti-
body. The intensity of the PY419-Src label among the treatments was normalized over the Src signal (n=3). (B and C) After treatment, O2 consumption was measured (n=4–5) in
the intact 143B and DU145 cells grown in glucose (glu) and galactose (gal) DMEM during the basal, oligomycin and CCCP respirations states. Means demarcated with an * are sig-
niﬁcantly different (pb0.05) from the control according to the Student's t-test.
722 E. Hebert-Chatelain et al. / Biochimica et Biophysica Acta 1817 (2012) 718–725spectrometry identiﬁed this band as NDUFB10 (Table 2) and the
phosphorylated protein was further conﬁrmed by immunoblotting
with an antibody to NDUFB10 (Fig. 5). Therefore, Src kinase seems
to sustain mitochondrial respiration by phosphorylating the
NDUFB10 subunit of complex I.
3.5. Other mitochondrial parameters inﬂuenced by Src inhibition
Because mitochondrial ATP production does not seem to be the
most important player in the proliferation of 143B and DU145 cells,
the Src kinase-mediated maintenance of mitochondrial respiration
should be related to other mitochondrial function(s). As complex I in-
hibition is known to increase ROS levels [26,27], we evaluated ROS
levels after treatment with Src inhibitors using CM-H2DCFDA andTable 1
Mean (S.D.) values of the different respiration (pmol O2 s−1 10−6 cells) steps for the
intact and untreated 143B and DU145 cells grown in glucose or galactose DMEM
(n=4–5). * indicates that the respiration values are statistically different (p≤0.05) be-
tween the glucose and galactose DMEM.
143B DU145
Glucose Galactose Glucose Galactose
Basal 34.2 (3.5) 52.3 (5.4)* 37.1 (10.9) 56.2 (1.6)*
Oligomycin 11.6 (2.5) 14.7 (3.2) 17.4 (4.6) 19.5 (3.5)
CCCP 81.7 (12.7) 119.5 (4.2)* 65.4 (14.8) 114.7 (13.5)*MitoSox probes (Fig. 6A and B). As no difference in these ﬂuorescence
probes was noted among the treatments, it seems that Src kinase did
not inﬂuence ROS production, at least in our experimental conditions.
Since the inhibition of complex I can also reduce the mitochondrial
membrane potential [28,29], we then measured TMRM ﬂuorescence.
Accordingly with increased OXPHOS activity in galactose DMEM, the
TMRM signal was higher in the galactose-grown control cells than
in the glucose-grown control cells. This result could be in accordance
with an increase in mitochondrial content [24] and is consistent with
the increase of respiration in the galactose medium as compared to
the glucose medium (see Table 1). Src inhibition treatments induced
a clear decline of TMRM ﬂuorescence in 143B gal and DU145 gal, but
not in 143B glu and DU145 glu (Fig. 6C). These results clearly suggest
that the Src kinase-mediated phosphorylation of NDUFB10 maintains
the mitochondrial membrane potential (ΔΨ) when the cells are
maintained in galactose medium.
4. Discussion
Several cancer cells and tumors exhibit increased aerobic glycoly-
sis, which is known as the Warburg effect [2,3]. Modiﬁcations of mi-
tochondria have also been observed, for example: a decrease in
mitochondrial biogenesis [30], the alteration of ETS complexes activ-
ities [31], a truncated TCA cycle with citrate efﬂux [7], an increase in
the binding of hexokinase II to mitochondria [32,33], changes in mito-
chondria shape and size [34], and the accumulation of mutations in
Fig. 4. Inhibition of Src kinase leads to a decrease in complex I activity in the 143B and DU145 cells. (A) After treating the 143B and DU145 cells grown in glucose (glu) and galactose
(gal) DMEMwith DMSO (as control), PP2 (5 μM) or SU6656 (10 μM) for 4 h, the O2 consumption was measured (n=4–5) in digitonin-permeabilized cells during basal respiration,
pyruvate–malate–ADP driven respiration (St3 PMD) and rotenone–succinate–ADP driven respiration (St3 SD). (B and C) After treatment, the cells were harvested and complexes I,
II, III and IV as well as citrate synthase enzymatic activities (n=3) were measured as in [51]. (D) After the treatments, the cells were harvested and the mitochondrial fractions were
immunoblotted with the NDUFS2 antibody (marker of complex I), the COX II antibody (marker of complex IV) and porine (as a loading control). All of the blots are representative of
the three independent experiments. Means demarcated with an * are signiﬁcantly different (pb0.05) from the control according to the Student's t-test.
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changes lead to increased glycolytic ATP production and lower mito-
chondrial ATP production, as we observed for the 143B and DU145
cells where ATP was mostly produced (approximately 90%) by glycol-
ysis. Despite this low mitochondrial energy production in glycolyticFig. 5. Src kinase induces the tyrosine phosphorylation of the complex I subunit
NDUFB10. The immunoprecipitation of complex I from 143B and DU145 was per-
formed after the incubation of isolated mitochondria with ATP (1 mM) or ATP with
PP2 (10 μM). The immunoprecipitates were then western blotted and phosphotyrosine
was detected with the PY20 antibody. The identity of the phosphorylated subunit was
ﬁrst determined by mass spectrometry (as shown in Table 2) and further conﬁrmed by
labeling the NDUFB10 subunit. Immunoblots are only presented for complex I immu-
noprecipitated from the DU145 mitochondrial fractions although the same results
were obtained from the 143B cells (L.C.: light chain).cells, the inhibition of OXPHOS can lead to a signiﬁcant decrease in
proliferation, as we observed for the 143B and DU145 cells (Fig. 1).
Therefore, mitochondrial metabolism seems to be important in main-
taining the important proliferative phenotype of highly glycolytic
cancer cells. Interestingly, most of the precursors that are used by bio-
synthesis pathways are produced by the TCA cycle. For example, most
of the citrate is exported out of the mitochondria and used for de
novo fatty acid synthesis in cancer cells. The increased glutamineTable 2
Proteins identiﬁed by LC–MS–MS in the tyrosine-phosphorylated band of complex I im-














P02768 Serum albumin 5 2 2.46 69.322
P47985 Complex III subunit
Rieske
3 3 15.69 29.649
O96000 Complex I beta
subcomplex subunit 10
3 3 20.93 20.763
P21291 Cysteine and glycine-
rich protein
2 2 19.17 20.554
P04083 Annexin A1 2 2 7.80 38.690
Fig. 6. The impact of Src kinase inhibition on mitochondrial membrane potential and
ROS levels. After treating the 143B and DU145 cells grown in glucose (glu) or galactose
(gal) DMEM with DMSO (as control), PP2 (5 μM) or SU6656 (10 μM) for 4 h, the ROS
levels were evaluated by the ﬂuorescence of (A) CM-H2DCFDA (mainly indicative of cy-
tosolic ROS) and (B) MitoSox (mainly indicative of mitochondrial ROS) probes while
the mitochondrial membrane potential was evaluated by the (C) TMRM signal
(n=3). Means demarcated with an * are signiﬁcantly different (pb0.05) from the con-
trol according to the Student's t-test.
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cells also allow higher biosynthesis rates as well as the production
of TCA cycle intermediates in order to maintain the mitochondrial
membrane potential [37,38]. Therefore, mitochondrial metabolism is
essential to sustain the high proliferative phenotype of cancer cells,
as we observed in the 143B and DU145 cells. Indeed, the depletion
of mitochondrial DNA and OXPHOS in different cancer cell lines can
induce lower tumorigenic properties and metastatic potential, both
in vitro and in vivo [39,40].
Interestingly, the Src-dependent tyrosine phosphorylation of mi-
tochondrial proteins increases concomitantly with stimuli triggering
cell proliferation in neuroblastoma cells [41]. According to our results,
we propose that the increase in Src kinase activity is important for the
proliferative phenotype of cancer cells via its effect on complex I. Our
study showed that Src kinase is present within the mitochondria of
the 143B and DU145 cells where it plays a major role in in vitro tyro-
sine phosphorylation. The inhibition of Src kinase in the 143B and
DU145 cells led to the inhibition of complex I-dependent respiration
but no effect was observed with complex II substrates. This decrease
in respiration was shown to be due to a speciﬁc decrease in the com-
plex I enzymatic capacities (Fig. 3), which was probably explained by
the reduced Src-dependent phosphorylation of the NDUFB10 subunit
(Fig. 4). Src kinase inhibitors did not affect complex IV in 143B andDU145 cells, contrasting with the ﬁndings of Miyazaki and colleagues
[13] who showed that Src kinase increased cytochrome c oxidase
activity through phosphorylation of its subunit II in osteoclasts. The
high energy demanding activity of bone resorption of osteoclasts seems
to be highly dependent of mitochondrial energetic production. Indeed,
the stimulation of oxidative metabolism by Src kinase-mediated
phosphorylation of the complex IV subunit II was essential for maintain-
ing the function of osteoclasts [13]. In contrast, mitochondrial ATP pro-
duction does not seem important in 143B and DU145, at least for
proliferation. Therefore, the absence of Src kinase impact on cytochrome
c oxidase in 143B and DU145 cells could be explained by the different
metabolic phenotype of cancer cells and osteoclasts.
The inhibition of Src kinase induced a clear decrease in the mito-
chondrial membrane potential in 143B and DU145 cells maintained
in galactose medium (Fig. 6). In such conditions, Src kinase could pre-
serve the mitochondrial membrane potential by inducing the phos-
phorylation of NDUFB10. Most mitochondrial functions, such as
importing proteins into or across the mitochondrial inner membrane,
require sufﬁcient ΔΨ [42–44], showing the possible importance of
this regulation of ΔΨ by Src kinase. However, it would be too hasty
to deﬁnitively conclude about the impact of Src-mediated phosphor-
ylation of NDUFB10 on mitochondrial membrane potential since Src-
kinase inhibitors failed to induce a similar decrease in cells grown in
glucose DMEM (Fig. 6).
Src kinase-mediated phosphorylation of NDUFB10 could participate in
the establishment of the proliferative phenotype of cancer cells through
different mechanisms. The increase in Src kinase activity could be
important formaintaining a certain steady-state in terms ofmitochondri-
al function in cancer cells. As themain role of themitochondria is not ATP
production in these cells, the Src kinase mediated increase of complex I
activity and respiration should be related to other mitochondrial func-
tions. For example, the modulation of complex I activity by Src kinase
could be important in the control of mitochondrial redox potential and
NAD+/NADH ratio. By increasing complex I activity and NADH consump-
tion, Src kinase could also ensure a sufﬁcient ﬂux through the TCA cycle,
allowing an important production of TCA cycle intermediates used for
biosynthesis pathways. The preservation ofΔΨ via Src-dependentmodu-
lation of complex I activity could ensure the adequate importation of
mitochondrial proteins (such as TCA cycle enzymes) into the mitochon-
dria, enabling biosynthesis and proliferation. Further studieswill be need-
ed to test these hypotheses.
The structure of complex I is not completely understood but
NDUFB10 seems to be located on the matrix side of subcomplex Iβ
within the hydrophobic arm of complex I [45]. Four accessory sub-
units, including NDUFB10, contain cysteine-rich motifs and it has
been proposed that these subunits might be involved in iron-cluster
assembly [46,47]. The phosphorylation of NDUFB10 by Src kinase
could therefore affect the transfer of electrons within complex I, and
increase its enzymatic activity (Fig. 4). Complex I transfers electrons
from NADH to ubiquinone and simultaneously pumps protons from
the mitochondrial matrix to the intermembrane space. This transloca-
tion of protons is thought to occur in the membrane arm but the exact
mechanism is unknown as several models still exist [45]. Therefore,
NDUFB10 could also act as a regulator of complex I by modulating
proton translocation through Src-mediated phosphorylation since
Src inhibition led to a decreased mitochondrial membrane potential,
at least for cells maintained in galactose medium (Fig. 6). Obviously,
a more accurate understanding of the structure of complex I and of
its proton translocation will be needed to conﬁrm these mechanisms.
5. Conclusion
In conclusion, we propose that the Src-dependent phosphoryla-
tion of NDUFB10 could participate in the development of the prolifer-
ative phenotype of glycolytic cancer cells such as 143B and DU145
cells by preserving complex I activity. Src kinase is involved in several
725E. Hebert-Chatelain et al. / Biochimica et Biophysica Acta 1817 (2012) 718–725properties of cancer cells such as increased survival, migration and
proliferative capacities. While previous studies have shown that
high Src kinase activity increases aerobic glycolysis (13–14), this
study demonstrates that Src also participates in the maintenance of
mitochondrial functions in cancer cells. The oncogene c-Myc is also
well known for simultaneously stimulating aerobic glycolysis
[48,49] and maintaining mitochondria function [37,50], suggesting
that Src kinase should be also considered as a pinpoint control in
the establishment of proliferative phenotypes.
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